Puma Biotechnology Investor Presentation — August 2024

Document content

This presentation contains forward -looking statements, including statements regarding commercialization of NERLYNX® and the pote ntial indications

and development of our drug candidates. All forward -looking statements involve risks and uncertainties that could cause our actu al results to differ

materially from the anticipated results and expectations expressed in these forward -looking statements. These statements are bas ed on our current

expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors,

which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, genera lly, from the global

COVID -19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Com mission from time to

time, including our Annual Report on Form 10 -K for the year ended December 31, 2023 and subsequent filings. Readers are cautione d not to place

undue reliance on these forward -looking statements, which speak only as of the date hereof. We assume no obligation to update th ese forward -looking

statements except as required by law.Forward -Looking Safe -Harbor Statement3

Copyright 2024 Puma Biotechnology

Others (VA, DOD)Hub Services

Specialty Pharmacy Network (SP)

Specialty Distributor Network (SD)

ASD / Oncology Supply

DMS Pharmaceutical Group

Inc.Puma’s Pharmacy and Distributor Network4

Copyright 2024 Puma Biotechnology51.6

Q2'2023 Q2'2024Net Revenue (in $MM)

Q1'2024 Q2'2024Net Revenue (in $MM)~14% decline in Q2’24 compared to Q2’23 ~10% increase in Q2’24 compared to Q1’24